Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Mitch , nice talking with you. Per our conversation, I'll garner help with the cover. Best...
If that's your true position, then you haven't done enough DD on the company, science and trial. The results were better than what the company was expecting. It included some very positive "unexpected therapeutic benefits".
This is purely an over reaction initiated by AF and the cabal. This will settle out and then turnaround with the next catalyst: PK/PD analysis, P3 announcement and/or partnership.
I knew you were, as was I.
But still might be worth trying something to raise awareness there. Cannot hurt.
Great! Let us know if you get a response.
The cabal really want to drive out retail... before the next catalyst, which could happen any week.
Does anyone here know Warren Buffett to convince him to invest a measly $5-$10M in AVXL?
That's not the kind of press or media I'm referring to.
Since this is a temporary orchestrated attack, it would be a bad idea to sell here. Hold out for next catalyst, at least: PK/PD analysis, P3 announcement and/or partnership.
Just wish we could get some positive press... some media coverage or interview that can generate the awareness we need.
Translation: There is no basis. LoL!
So, what's the basis for AXON to be valued at >$1.5B, with a previously failed drug?
I'm fairly certain that the first halt, at 1:01p, had to have been caused by the cabal. No retail investor could have received, read and digested the PR that quickly. It was a planned attack, regardless of the data presented.
How can you argue the point when AXON has a MC of > $1.5B with a previously failed drug?
It amazes me that several posters here still DO NOT UNDERSTAND THE PURPOSE AND DESIGN OF A P2 TRIAL. The FDA guided Anavex in its P2 trial design to be an adaptive, open label trial of 32 patients for the purpose of identifying maximum and optimal dosages, as well as the results from the two study arms: monotherapy and combo with donepezil. There's not supposed to be a larger number than 32 nor a placebo arm. The results of this adaptive, open label P2 will greatly increase the chances for a successful P3, which will indeed be larger (multiple locations) and potentially have a placebo arm, but more likely an SoC arm.
I disagree... what has hurt us are the planned attacks by the shorting cabal. PERIOD!
I agree... Anavex isn't a charity organization. Something is happening behind the scenes that warrants his increased pay and options. The nice thing about the options are the strike prices at $6.25 and $7.
I believe that we'll find the stories to be true and there will be more to come...perhaps not as impressive, but good nonetheless. Just because the pooled data didn't produce an amazing graph, doesn't mean that amazing improvements aren't happening. Don't discount the benefits of reduced depression, improved mood, demeanor and attitude.
Don't you think that the media story would have been aired with or without MacFarlane's participation? I do...
All I said was "it would seem that partner discussions are in progress". I didn't say that we have a partner lined up. You on the other hand, seem to think that nothing is happening since you've heard nothing. Which do you think is more accurate?
Because that is the normal course of progress, as stated by the CEO, who isn't sitting around doing nothing. You think that just because you hear nothing, that nothing is being done. Geez!
I think you're overlooking one VERY IMPORTANT fact... the FDA was involved in designing Anavex's adaptive open Phase2 trial. If the company and FDA are comfortable with the results, and they secure a partner and/or funding, this will move directly to Phase3.
Good points. I'm sure Clayton Parker has a very good relationship with the regulators and are having some conversations.
The "unusual trading activity" noted with the earlier subpoena, likely had to do with the short attack a few days BEFORE news was released in Nov. This time the cabal waited until the time of the release (but before anyone could appreciably ingest it).
2-73 + cannabinoid compound... interesting concept!
Agreed... It would seem that partner discussions are in progress.
Thanks, but my question has more to do with what the actual data analysis might reveal (in a PR) and whether it could cause a significant price recovery?
What can we expect from the long-awaited PK/PD data (that should materialize fairly soon)? I would think it should provide further confirmation of the drug's success. If so, then we could see a significant SP recovery on the PR.
Thoughts?
The question is how many DIFFERENT shares were involved in that volume? Could be a lower percentage than we might think, via back and forth trading/rundown.
Found the article... It is for P3 trial design...dose optimization.
http://www.dddmag.com/article/2007/09/modeling-success-pkpd-testing
I vote for that! :)
I'm not an expert in this field, but someone did post an article on some board about the benefits of late stage PK/PD data. I believe it had to do with dose optimization, but not sure. I'll try to find the article.
That's quite a stretch...
...or the placebo arm is replaced with donepezil, since it's the current SoC.
Agreed, not enough time to read the PR and react. This was a short attack no matter what.
I'm not so sure it would have screamed up on better data. With all the shorted shares (4M+), the AF and JF bashing tweets and pre-scripted hit pieces, they were poised for an attack. But I guess we'll never really know.
I'm not, but that's certainly an option for going deeper into the trial.
I said START, not finish. A P3 trial doesn't need a partner to start, but it would be preferable if we did.
I don't disagree. Doesn't the SEC get support/funding from trade activity?
We don't need a partner to start a P3 trial; we have enough funds to start.
I hear what you're saying, but don't you think the stories would have been produced anyway with or without MacFarlane? I think so.
Tom, MacFarlane did not suggest these patients were representative of the entire trial. Your assumptions are wrong. We need to stop with blaming MacFarlane, as we'll soon learn the stories are real and that we'll hear more success stories in due time.
Folks, the data is GOOD! And as I said before...we must understand and take into consideration the benefits of decreased depression, improved mood, demeanor and attitude. Those are key elements to motivate oneself to do what you used to like doing.